Literature DB >> 233356

Natural history of perinatal cytomegaloviral infection.

C A Alford, S Stagno, R F Pass.   

Abstract

Epidemiological data presented here indicate that cytomegaloviral (CMV) infection is one of the most common perinatal infections found in human beings. Transmission to the offspring occurs in utero at birth and postnatally. Intrauterine infection results from primary or recurrent maternal involvement, the latter being more common in populations where infection is initially acquired during childhood or adolescence, such as in low socioeconomic settings. Congenital infection is usually subclinical with either type of maternal involvement but primary infection has a greater tendency to produce disease in the fetus. About 20% of the offspring infected in utero are damaged, infrequently with generalized disease, but more often with auditory involvement. The latter can develop in utero or postnatally and can be progressive. The major cause of recurrent maternal infection according to restriction enzyme analysis is reactivation of latent virus, which occurs in the face of substantial maternal humoral immunity, even with intrauterine transmission of virus. Reinfection by exogenous virus remains a lesser possibility for maternal recurrences. Even more commonly, CMV can be transmitted at birth from the infected maternal genital tract and postnatally through infected breast milk, especially in highly immune populations. With the possible exception of early pneumonia, these infections appear to be innocuous.

Entities:  

Mesh:

Year:  1979        PMID: 233356     DOI: 10.1002/9780470720608.ch9

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  7 in total

1.  Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.

Authors:  William J Britt
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression.

Authors:  R S Fujinami; J A Nelson; L Walker; M B Oldstone
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

3.  Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus.

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

5.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  A comparison of cervical cytomegalovirus (CMV) excretion in gynaecological patients and post-partum women.

Authors:  W A Knowles; S D Gardner; H Fox
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

7.  Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells.

Authors:  B A Krishna; B Lau; S E Jackson; M R Wills; J H Sinclair; E Poole
Journal:  Sci Rep       Date:  2016-04-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.